Organization · Venture Capital
Genesys Capital
Genesys Capital is a Toronto-based venture capital firm established in 2000, specializing in early-stage investments in life sciences, healthcare, and biotechnology. The firm emphasizes hands-on partnerships with founders and strategic guidance.
Overview
What Genesys Capital does
What Genesys Capital is
Genesys Capital is a Toronto-based venture capital firm established in 2000, specializing in early-stage investments in life sciences, healthcare, and biotechnology. The firm emphasizes hands-on partnerships with founders and strategic guidance.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2000
- Approximate age
- About 26 years
- Structured capabilities
- Funder
- Last reviewed
- April 30, 2026
Official channels
Find Genesys Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Genesys Capital as a funder
Investment thesis
Genesys Capital's thesis is to discover, build, and enable early-stage life-science companies that can address meaningful unmet medical needs. The firm emphasizes early access to academic/research discoveries, deep scientific diligence, and a create-and-build strategy that pairs capital with hands-on company formation, board participation, and long-term support.
Focus narrative
Genesys Capital invests exclusively in early-stage life sciences companies. The firm has raised over $400 million across five venture funds and has a portfolio of 44 companies. Their investment strategy emphasizes collaboration with scientific founders and entrepreneurs to create and build innovative healthcare solutions.
Value beyond capital
Genesys Capital provides deep scientific diligence, access to a robust network of research institutions, and hands-on support in company formation and governance. The firm is particularly suited for founders needing assistance with syndicate formation, clinical/commercial positioning, and navigating cross-border life sciences networks.
Focus and fit
- Stages
- Seed · Series A · Friends and Family · Accelerator
- Regions
- North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 44
- Recorded notable exits
- Fusion Pharmaceuticals, Inversago Pharma, Epocal, and Naurex
Portfolio context
Notable portfolio companies include: Fusion Pharmaceuticals Inc.: Acquired by AstraZeneca for $2.4 billion. Inversago Pharma: Acquired by Novo Nordisk for $1.1 billion. Profound Medical Inc.: A medical technology platform focused on MRI-guided ultrasound devices for various medical applications. Adapsyn Bioscience Inc.: A biotechnology company that develops novel medicines from small molecule natural products using AI and genomic data.
Common questions
What to know about Genesys Capital
Upseed classifies Genesys Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 30, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.